Dietary linoleic acid lowering alone does not lower arachidonic acid or endocannabinoids among women with overweight and obesity: A randomized, controlled trial
Courville AB, Majchrzak-Hong S, Yang S, Turner S, Wilhite B, Ness Shipley K, Horneffer Y, Domenichiello AF, Schwandt M, Cutler RG, Chen KY, Hibbeln JR, Ramsden CE
Lipids · 4 citas
Etiquetas de revisión
Alimentación controladaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
- Consumo medido con
- Comida provista por los investigadores
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institutes of Health
- Gobierno
- National Institute on Alcohol Abuse and Alcoholism
- Gobierno
- National Institute on Aging
- Gobierno
- National Institute of Diabetes and Digestive and Kidney Diseases
- Gobierno
- NIAAA NIH HHS
- Gobierno
- Intramural NIH HHS
- Gobierno
- NIDDK NIH HHS
- Gobierno
- NIA NIH HHS
- Subvenciones
- National Institutes of Health (Z99 DK999999)
Según 8 financiadores declarados.
Publicación
- Publicado
- 2023-11-01 · Lipids · vol. 58 · número 6 · págs. 271–284
- Editorial
- Wiley
- Citado
- 6 citas · más que el 72% de estudios similares · 0.9× el promedio de su campo
- Referencias
- 57 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Fatty Acid Research and Health · Cannabis and Cannabinoid Research · Inflammatory mediators and NSAID effects
- Palabras clave
- linoleic acid, arachidonic acid, endocannabinoids, omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, 2-arachidonoylglycerol, anandamide, dietary fatty acid composition, overweight, obesity, premenopausal women, inflammation
- MeSH
- humans, obesity, docosahexaenoic acids, eicosapentaenoic acid, fatty acids, arachidonic acids, arachidonic acid, linoleic acid, endocannabinoids, diet, adult, female, overweight
13 autores
- Amber B. Courville🇺🇸 · autor de correspondenciaNational Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases
- Sharon F. Majchrzak‐Hong🇺🇸National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
- Shanna B. Yang🇺🇸National Institutes of Health; National Institutes of Health Clinical Center
- Sara Turner🇺🇸National Institutes of Health; National Institutes of Health Clinical Center
- Breanne C. Wilhite🇺🇸National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
- Katherine Ness Shipley🇺🇸National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
- Yvonne R. Horneffer🇺🇸National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
- Anthony F. Domenichiello🇺🇸National Institutes of Health; National Institute of Neurological Disorders and Stroke; National Institute on Alcohol Abuse and Alcoholism
- Melanie L. Schwandt🇺🇸National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
- Roy G. Cutler🇺🇸National Institutes of Health; National Institute on Aging
- Kong Y. Chen🇺🇸National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases
- Joseph R. Hibbeln🇺🇸National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism
- Christopher E. Ramsden🇺🇸National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism; National Institute on Aging
Resumen
El texto original del estudio, en el idioma en que se publicó.
The linoleic acid (LA)-arachidonic acid (ARA)-inflammatory axis suggests dietary LA lowering benefits health because it lowers ARA and ARA-derived endocannabinoids (ECB). Dietary LA reduction increases concentrations of omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and DHA derived ECB. The aim of this study was to examine targeted reduction of dietary LA, with and without EPA and DHA, on plasma EPA and DHA and ECB (2-arachidonoyl glycerol [2-AG], anandamide [AEA], and docosahexaenoyl ethanolamide [DHA-EA]). Healthy, pre-menopausal women (n = 62, BMI 30 ± 3 kg/m2 , age 35 ± 7 years; mean ± SD) were randomized to three 12-week controlled diets: (1) high LA, low omega-3 EPA and DHA (H6L3); (2) low LA, low omega-3 EPA and DHA (L6L3); or (3) low LA, high omega-3 EPA and DHA (L6H3). Baseline plasma fatty acids and ECB were similar between diets. Starting at 4 weeks, L6L3 and L6H3 lowered plasma LA compared to H6L3 (p < 0.001). While plasma ARA changed from baseline by 8% in L6L3 and -8% in L6H3, there were no group differences. After 4 weeks, plasma EPA and DHA increased from baseline in women on the L6H3 diet (ps < 0.001) and were different than the H6L3 and L6L3 diets. No differences were found between diets for AEA or 2-AG, however, in L6L3 and L6H3, AEA increased by 14% (ps < 0.02). L6H3 resulted in 35% higher DHA-EA (p = 0.013) whereas no changes were seen with the other diets. Lowering dietary LA did not result in the expected changes in fatty acids associated with the LA-ARA inflammatory axis in women with overweight and obesity.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.